Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Blood pressure increase
Single dose administration of lasmiditan may lead to a transient increase in blood pressure. In
non-elderly healthy volunteers a mean increase from baseline in ambulatory systolic and diastolic
blood pressure of approximately 2 to 3 mm Hg one hour after administration of 200 mg lasmiditan
was observed, compared to an increase of about 1 mm Hg for placebo. In healthy volunteers over
65 years of age, the mean increase from baseline in ambulatory systolic blood pressure was 7 mm Hg
one hour after administration of 200 mg lasmiditan compared to a mean increase of 4 mm Hg for
placebo. By 2 hours, there were no increases in mean blood pressure with lasmiditan compared to
placebo. Clinical data for the use of lasmiditan in patients with ischemic heart disease is limited.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Hypersensitivity
Events of hypersensitivity, including angioedema, rash, and photosensitivity reaction, occurred in
patients treated with lasmiditan. In clinical trials, hypersensitivity was reported in 0.1 % of patients
treated with lasmiditan compared to no patients in the placebo group; all events were mild to moderate
in severity and occurred within minutes to a day after dosing with lasmiditan. If a serious or severe
hypersensitivity reaction occurs, appropriate therapy should be initiated and administration of
lasmiditan should be discontinued.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Dizziness
In clinical trials, dizziness was the most common adverse reaction, reported in 19.9 % of patients. It
was generally mild to moderate in severity (severe dizziness 1.2 %) and self-limiting with a median
time to onset of 0.7 hours and a median duration of 2 hours. No accidents or injuries were reported in
patients reporting dizziness. The frequency of patients reporting dizziness, and other common adverse
events, typically decreases with repeat dosing.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-02-06T14:15:00Z · SHA-256 1e249810461a190ad08f26cfa9c8836cc5710c80820c828a4ea6df354808f0a7 · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 5258–5572 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.